The publication of a large number of randomised controlled trials in heart failure patients over the last 25 years has allowed the development of several excellent evidence-based guidelines. Revised SIGN guidelines for heart failure are due for publication this year. The major challenge facing us now is the implementation of these evidence-based therapies and the allocation of resources to allow the development and assessment of emerging technologies to ensure that patients receive the treatments they need.
